School of Cancer and Enabling Studies, University of Manchester, Paterson Institute for Cancer Research, Manchester, UK.
BMC Med. 2010 Nov 16;8:73. doi: 10.1186/1741-7015-8-73.
Genomic data from breast cancers provide additional prognostic and predictive information that is beginning to be used for patient management. The question arises whether additional information derived from other 'omic' approaches such as metabolomics can provide additional information. In an article published this month in BMC Cancer, Borgan et al. add metabolomic information to genomic measures in breast tumours and demonstrate, for the first time, that it may be possible to further define subgroups of patients which could be of value clinically. See research article: http://www.biomedcentral.com/1471-2407/10/628.
乳腺癌的基因组数据提供了额外的预后和预测信息，这些信息开始被用于患者管理。问题是，其他“组学”方法（如代谢组学）获得的额外信息是否可以提供更多信息。在本月发表在 BMC 癌症杂志上的一篇文章中，Borgan 等人在乳腺癌肿瘤的基因组测量中加入了代谢组学信息，并首次证明，进一步定义可能具有临床价值的患者亚组是有可能的。见研究文章：http://www.biomedcentral.com/1471-2407/10/628。
